Overview
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
Status:
Completed
Completed
Trial end date:
2007-06-01
2007-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Genzyme, a Sanofi CompanyTreatments:
Gefitinib
Criteria
Inclusion Criteria:- Failure of either first-line and/or second-line chemotherapy either of which was
platinum-based (the prior regimen must have failed the subject because of toxicity or
progression of tumor
- Prior histologic or cytologic confirmation of locally advanced or metastatic (IIIB/IV)
NSCLC
Exclusion Criteria:
- Subjects who have received second-line or subsequent chemotherapy
- Any evidence of clinically active interstitial lung disease (patients with chronic,
stable, radiographic changes who are asymptomatic, need not be excluded)